Correlations between expressions of TUBB3 gene mRNA and prognosis in 92 patients of non-small cell lung cancer
ZHAO Yunlong1, LI Jingbo1, ZHAO Yingnan1, CHEN Ping1, LIU Bo1, LIU Yang2
1. Department of Thoracic Surgery, Fourth Medical Center of PLA General Hospital,Beijing100048,China; 2. Department of Thoracic Surgery, PLA General Hospital, Beijing 100853,China
Abstract：Objective To evaluate the correlations between the expression of TUBB3 mRNA and the prognosis of NSCLC patients who can be treated surgically. Methods The expression of TUBB3 gene mRNA was detected with branch DNA liquid chips in 92 NSCLC patients who were followed up for 60 months. Results Low expressions of TUBB3 promised longer overall survival (48.7 vs 35.8 months, HR=1.56, 95% CL:1.45-2.56, P=0.017) in these patients. The median progression-free survival was longer in patients with low expressions of TUBB3 mRNA than in those with high expressions (35.7 months vs 23.5 months, P=0.001, HR=1.33,95% Cl:1.06-2.32). Conclusions TUBB3 mRNA expressions may be a factor that can help predict the prognosis of NSCLC patients.
Detterbeck F C, Chansky K, Groome P, et al. The IASLC lung cancer staging project: methodology and validation used in the development of proposals for revision of the stage classification of nsclc in the forthcoming (eighth) edition of the tnm classification of lung cancer[J]. J Thorac Oncol, 2016, 11(9):1433-1446.
Laufs V, Altieri B, Sbiera S, et al. ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas[J]. Eur J Endocrinol, 2017, 178(2): 181-188.
[6]
Mariani M, Karki R, Spennato M, et al. Class Ⅲ β-tubulin in normal and cancer tissues[J]. Gene, 2015, 563(2):109-114.
[7]
Xuemei X, Jie L, Wanjun L, et al. BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy[J].Oncotarget,2017, 8(46):80869-80877.
[8]
Lafuente S A, Zuniga A, Galbis J M, et al. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer[J]. Clin Transl Oncol,2015,18(8):798-804.
[9]
Okuda K, Tatematsu T, Yano M, et al. The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair crosscomplementation group 1 and class Ⅲ βtubulin, and the therapeutic effect of S1 or carboplatin plus paclitaxel in nonsmallcell lung cancer[J]. Mol Clin Oncol,2018,9(1):21-29.
[10]
Levallet G, Bergot E, Antoine M, et al. High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway[J]. Mol Cancer Ther,2012,11(5):1203-1213.
[11]
Reiman T, Lai R, Veillard A S, et al. Cross-validation study of class Ⅲ beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials[J].Ann Oncol,2012,23(1):86-93.
[12]
Hirai Y, Yoshimasu T, Oura S, et al. Is class Ⅲ beta-tubulin a true predictive marker of sensitivity to vinorelbine in non-small cell lung cancer? Chemosensitivity data evidence[J]. Anticancer Res,2011,31(3):999-1005.
[13]
Mccarroll J A, Gan P P, Erlich R B, et al. TUBB3/βⅢ-tubulin acts through the PTEN/ AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer[J]. Cancer Res,2015,75(2):415-425.
[14]
Gong L, Mao W, Chen Q, et al. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study[J]. Cancer Chemother Pharmacol,2019,83 (4):639-664.
[15]
Zhang Y, Yang H, Liu J, et al. High expression levels of class Ⅲβtubulin in resected nonsmall cell lung cancer patients are predictive of improved patient survival after vinorelbinebased adjuvant chemotherapy[J]. Oncol Lett,2013,6(1):220-226.
2020, Vol. 31 
